These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 32204955)

  • 1. Targeting MCL-1 in hematologic malignancies: Rationale and progress.
    Wei AH; Roberts AW; Spencer A; Rosenberg AS; Siegel D; Walter RB; Caenepeel S; Hughes P; McIver Z; Mezzi K; Morrow PK; Stein A
    Blood Rev; 2020 Nov; 44():100672. PubMed ID: 32204955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia.
    Tron AE; Belmonte MA; Adam A; Aquila BM; Boise LH; Chiarparin E; Cidado J; Embrey KJ; Gangl E; Gibbons FD; Gregory GP; Hargreaves D; Hendricks JA; Johannes JW; Johnstone RW; Kazmirski SL; Kettle JG; Lamb ML; Matulis SM; Nooka AK; Packer MJ; Peng B; Rawlins PB; Robbins DW; Schuller AG; Su N; Yang W; Ye Q; Zheng X; Secrist JP; Clark EA; Wilson DM; Fawell SE; Hird AW
    Nat Commun; 2018 Dec; 9(1):5341. PubMed ID: 30559424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
    Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S
    Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting.
    Slomp A; Moesbergen LM; Gong JN; Cuenca M; von dem Borne PA; Sonneveld P; Huang DCS; Minnema MC; Peperzak V
    Blood Adv; 2019 Dec; 3(24):4202-4214. PubMed ID: 31856269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents.
    Bolomsky A; Vogler M; Köse MC; Heckman CA; Ehx G; Ludwig H; Caers J
    J Hematol Oncol; 2020 Dec; 13(1):173. PubMed ID: 33308268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AML.
    Ewald L; Dittmann J; Vogler M; Fulda S
    Cell Death Dis; 2019 Dec; 10(12):917. PubMed ID: 31801941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pairing MCL-1 inhibition with venetoclax improves therapeutic efficiency of BH3-mimetics in AML.
    Hormi M; Birsen R; Belhadj M; Huynh T; Cantero Aguilar L; Grignano E; Haddaoui L; Guillonneau F; Mayeux P; Hunault M; Tamburini J; Kosmider O; Fontenay M; Bouscary D; Chapuis N
    Eur J Haematol; 2020 Nov; 105(5):588-596. PubMed ID: 32659848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. c-Myc plays a critical role in the antileukemic activity of the Mcl-1-selective inhibitor AZD5991 in acute myeloid leukemia.
    Liu S; Qiao X; Wu S; Gai Y; Su Y; Edwards H; Wang Y; Lin H; Taub JW; Wang G; Ge Y
    Apoptosis; 2022 Dec; 27(11-12):913-928. PubMed ID: 35943677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models.
    Punnoose EA; Leverson JD; Peale F; Boghaert ER; Belmont LD; Tan N; Young A; Mitten M; Ingalla E; Darbonne WC; Oleksijew A; Tapang P; Yue P; Oeh J; Lee L; Maiga S; Fairbrother WJ; Amiot M; Souers AJ; Sampath D
    Mol Cancer Ther; 2016 May; 15(5):1132-44. PubMed ID: 26939706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NA1-115-7, from Zygogynum pancheri, is a new selective MCL-1 inhibitor inducing the apoptosis of hematological cancer cells but non-toxic to normal blood cells or cardiomyocytes.
    Daressy F; Séguy L; Favre L; Corvaisier S; Apel C; Groo AC; Litaudon M; Dumontet V; Malzert-Fréon A; Desrat S; Roussi F; Robert A; Wiels J
    Biomed Pharmacother; 2022 Oct; 154():113546. PubMed ID: 35988426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DRP-1 is required for BH3 mimetic-mediated mitochondrial fragmentation and apoptosis.
    Milani M; Byrne DP; Greaves G; Butterworth M; Cohen GM; Eyers PA; Varadarajan S
    Cell Death Dis; 2017 Jan; 8(1):e2552. PubMed ID: 28079887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BCL2 and MCL1 inhibitors for hematologic malignancies.
    Roberts AW; Wei AH; Huang DCS
    Blood; 2021 Sep; 138(13):1120-1136. PubMed ID: 34320168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pyoluteorin derivatives induce Mcl-1 degradation and apoptosis in hematological cancer cells.
    Doi K; Gowda K; Liu Q; Lin JM; Sung SS; Dower C; Claxton D; Loughran TP; Amin S; Wang HG
    Cancer Biol Ther; 2014; 15(12):1688-99. PubMed ID: 25535900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphoma cells lacking pro-apoptotic BAX are highly resistant to BH3-mimetics targeting pro-survival MCL-1 but retain sensitivity to conventional DNA-damaging drugs.
    Diepstraten ST; Young S; La Marca JE; Wang Z; Kluck RM; Strasser A; Kelly GL
    Cell Death Differ; 2023 Apr; 30(4):1005-1017. PubMed ID: 36755070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
    Ma J; Zhao S; Qiao X; Knight T; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Wang G; Zhao L; Lin H; Wang Y; Taub JW; Ge Y
    Clin Cancer Res; 2019 Nov; 25(22):6815-6826. PubMed ID: 31320594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of XPO1 enhances cell death induced by ABT-199 in acute myeloid leukaemia via Mcl-1.
    Luedtke DA; Su Y; Liu S; Edwards H; Wang Y; Lin H; Taub JW; Ge Y
    J Cell Mol Med; 2018 Dec; 22(12):6099-6111. PubMed ID: 30596398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies.
    Choudhary GS; Al-Harbi S; Mazumder S; Hill BT; Smith MR; Bodo J; Hsi ED; Almasan A
    Cell Death Dis; 2015 Jan; 6(1):e1593. PubMed ID: 25590803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cotargeting of Bcl-2 and Mcl-1 shows promising antileukemic activity against AML cells including those with acquired cytarabine resistance.
    Liu F; Zhao Q; Su Y; Lv J; Gai Y; Liu S; Lin H; Wang Y; Wang G
    Exp Hematol; 2022 Jan; 105():39-49. PubMed ID: 34767916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and resensitizes acute myeloid leukemia to BCL-2 inhibition.
    Carter BZ; Mak PY; Tao W; Warmoes M; Lorenzi PL; Mak D; Ruvolo V; Tan L; Cidado J; Drew L; Andreeff M
    Haematologica; 2022 Jan; 107(1):58-76. PubMed ID: 33353284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel Mcl-1 inhibitor synergizes with venetoclax to induce apoptosis in cancer cells.
    Zhao T; He Q; Xie S; Zhan H; Jiang C; Lin S; Liu F; Wang C; Chen G; Zeng H
    Mol Med; 2023 Jan; 29(1):10. PubMed ID: 36658493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.